


ActiGraft^{PRO}

Autologous Wound Care System



A personalized approach to wound management

ActiGraft^{PRO} system is an autologous, point-of-care wound management solution created from your patient's whole blood. Once applied, the blood clot serves as a protective covering and may optimize the body's own healing potential.



PROVEN OUTCOMES

173% more patients healed in the intervention arm compared to standard of care using Intent to treat (ITT) population, giving **odds ratio of 2.73.**

EASILY ADAPTABLE

Single application of the 28 cm² whole blood clot can be applied up to **56 cm²** wound.

STREAMLINED PROCEDURE

Seamless process with **no centrifuge, 5-minute coagulation**, and the flexibility to draw and store blood up to 24 hours prior to the procedure.

CHOOSE WITH CONFIDENCE

Described by NCD 270.3 as a blood derived product, ActiGraft^{PRO} is **eligible for reimbursement under G0465.** Commercial payor reimbursement policies may vary.

NATURAL HEALING

Created from a patient's own peripheral whole blood, **even in the presence of blood thinners**, to provide the wound with an optimal, natural healing environment.


AUTOLOGOUS

A personalized solution for patients with religious constraints, **immediately available at point of care.**


Jump-start the natural healing cascade

Designed to meet the needs of today's wound clinics, ActiGraft^{PRO} offers practitioners a wound management solution that delivers a quick and easy procedure.


How ActiGraft^{PRO} Works



Applied directly to the wound surface, ActiGraft^{PRO} is created at point of care in 5 minutes by mixing fresh whole blood with proprietary coagulation powder.



ActiGraft^{PRO} utilizes whole blood, retaining the cellular contents required for the natural wound healing process.



Once applied, ActiGraft^{PRO} promotes the healing cascade and serves as a protective covering supporting the natural wound healing processes.

Eligible for reimbursement with Medicare and Medicare Advantage Plans.

ActiGraft^{PRO} is described by the National Coverage Determination (NCD 270.3) as a blood-derived product for non-healing wounds and is eligible for reimbursement nationally from Medicare and Medicare Advantage with HCPCS G0465.

HCPCS Code	HCPCS Description	Status Indicator	APC Description	Medicare National Average Payment Rate
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (Includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)	T	5054	PROVIDER FEE \$83.84 FACILITY (HOPD) \$2,107.97

CMS will cover autologous PRP for the treatment of chronic non-healing diabetic wounds for a duration up to 20 weeks, when prepared by devices whose Food and Drug Administration (FDA)-cleared indications include the management of exuding cutaneous wounds, such as diabetic ulcers. Coverage and reimbursement depend on individual payor(s) policies, medical necessity, and clinical documentation.

Ready to use right out of the box

The ActiGraft^{PRO} system provides single-use components needed for the safe and rapid preparation of Whole Blood Clot (WBC) from a small sample of a patient's own peripheral blood.



ActiGraft^{PRO} system components

Each ActiGraft^{PRO} system is comprised of an individual box that contains all the components needed to prepare an ActiGraft^{PRO} whole blood clot.

PRODUCT NUMBER	DESCRIPTION	BOX QTY	STORAGE	CLOT SIZE
RD2301	ActiGraft ^{PRO} system	5	41° F - 86° F	28 sq. cm.



Order and Customer Support

Phone: (817) 961-1288 | Fax: (866) 300-0431
www.legacymedicalconsultants.com
customerservice@legacymedicalconsultants.com